Personen

TOP 5 Publikationen:

1. Mertens L, Koslowski M, Betzler F, Brand M, Evens R, Kärtner L, Jungaberle A, Jungaberle H, Majic T, Schmitz C, Ströhle A, Scharf D, Spangemacher M, Wolff M, Assadi Z, Bahri S, Becher L, Färber LV, Kirchen N, Kulakova E, Kunz L, Meijer A, Rohrmoser B, Wellek S, Berger M, Gründer G. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.JAMA Psychiatry. 2026 Mar 18. [Epub ahead of print].
2. De Prisco M, Tapoi C, Oliva V, Strumila R, Takami C, Girone N, Macellaro M, de Salles Andrade JB, Schmitz C, Vieta E, Fico G. Clinical impact of obsessive-compulsive disorder comorbidity in bipolar disorder: a systematic review and meta-analysis.Eur Psychiatry. 2025 68(1):e142. Epub 2025 Aug 26.
3. Spangemacher M, Schmitz C, Cumming P, Färber LV, Hart XM, Uchida H, Gründer G. The sense and nonsense of antipsychotic combinations: A model for dopamine D receptor occupancy.Transl Psychiatry. 2025 15(1):348.
4. Reinwald J, Schmitz C, Skorodumov I, Kuchar M, Weber-Fahr W, Spanagel R, Meinhardt M. Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats.Transl Psychiatry. 2023 13(1):392.
5. Hart X, Schmitz CN, Gründer G. Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice.Front Psychiatry. 2022 13:832209.